BIVI (BioVie Inc.) Earnings per share growth rate in current year

Official company branding of biovieinc.com (BIVI)

BioVie Inc. develops innovative therapies for severe liver pathologies and neurodegeneration. The annual earnings per share growth vector on the GURU.Markets chart confirms a trend where the value has stabilized at 0.00. However, the expansion of Alzheimer's and Parkinson's disease programs is increasing laboratory expenses. The brand's high scientific authority and the trust of clinics ensure the company maintains a stable position.

BIVI (BioVie Inc) Earnings growth in current year history from 07/04/2022 to 11/14/2026

Analytical breakdowns and data insights for company biovieinc.com (BIVI)

- share price and consensus valuation forecast:
Price Chart BioVie Inc|BIVI - Analyst Consensus Forecast
- business market valuation indicators:
Market Value BioVie Inc.|BIVI - Total Company Value
- balance sheet equity data:
Accounting Value of a Share BioVie|BIVI - Book Capitalization|Market Value to Book Value Ratio biovieinc.com|BIVI - Company Total Assets
- debt and liquidity details:
Total Debt to Capital Coefficient BioVie Inc.|BIVI - Long-Term Debt to Equity|Current Liabilities to Capital BioVie Inc.|BIVI - Company Total Debt|Debt to Book Capitalization Ratio BioVie|BIVI - Company Long-Term Debts|Short-Term Debt Volume BioVie|Immediate Liquidity biovieinc.com
- net income and valuation multiples indicators:
BIVI - Net Income|Expected Net Income BioVie Inc.|BIVI - P/E Multiple|Market Cap to Projected Earnings BioVie Pharma|BIVI - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation BioVie|BIVI - Operating profit EBITDA|Net earnings per share for the last 12 months BioVie|BIVI - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months biovieinc.com|BIVI - Earnings growth in current year|Net earnings per share growth forecast for next year BioVie Inc.
- sales volume and revenue information:
BIVI - Revenue and Sales Volume|Company Future Sales BioVie Inc.|BIVI - Market Cap to Revenue|Price-to-Projected Revenue Ratio BioVie
Summary company analysis:BioVie Inc., BIVI
Mass-produced product of BioVie Inc.

BioVie Inc. focuses on the development of the innovative drug NE3107 to combat neuroinflammation in Alzheimer's and Parkinson's diseases. The commercialization efficiency of such developments directly impacts the net profit distributed per share. This metric measures the percentage deviation of the current EPS from the value of the same period last year. It allows for an assessment of the business's financial resilience to market shocks. By analyzing the shift in earnings per share compared to last year, an investor determines the company's profitability dynamics.

Direct competitors

ARWR (Arrowhead Pharmaceuticals Inc) - Earnings per share growth in current year|MIRM (Mirum Pharmaceuticals, Inc.) - Earnings growth in current year|Earnings per share growth rate in current year Dynavax Technologies Corporation DVAX|Earnings per share growth in current year Arbutus Biopharma Corporation (ABUS)|Expected net earnings per share growth this year Inventiva SA|Earnings growth in current year GYRE (Gyre Therapeutics Inc)|Earnings growth in current year Assembly Corp ASMB|Galectin Therapeutics - Earnings growth in current year|Earnings per share growth rate in current year GENFIT|DURECT Corp. (DRRX) - Earnings per share growth in current year|ALGS - Expected net earnings per share growth this year|Earnings per share growth in current year galmedpharma.com|NDRA: Earnings per share increase in current year|Earnings per share growth in current year Hepion Pharmaceuticals (HEPA)